The finding that LAMA4, BIRC7, GALNTL6, WNK2, and IGFBP2 are potential targets of miR-217 at different times of tumor evolution may help to develop stage-specific strategies, taking into account the differential expression of miR-217 in each stage of clear cell renal carcinoma progression. The gene discussed is IGFBP2; the disease is neoplasm.